Rh disease or Rh incompatibility (also known as erythroblastosis fetalis) occurs when a woman with Rh-negative blood conceives a child with Rh-positive blood. Red blood cells are destroyed (hemolysis) because of this incompatibility, leading to anemia and other symptoms in the infant. Symptoms vary in severity among affected infants and may include an unusual yellowish coloration of the skin (jaundice); swelling of the chest and abdomen due to the accumulation of fluid (edema); and/or a pale appearance of the skin. In more severe cases, affected infants may have experience life-threatening complications. Rh disease occurs only when a mother's blood is Rh-negative and her baby's blood is Rh-positive.
During the first pregnancy of an Rh-negative woman carrying an Rh-positive fetus, there are rarely any symptoms. However, the risks of sensitization increase with each subsequent pregnancy when the fetus is Rh-positive.
In Rh disease, red blood cells from the fetus cross the placenta and enter into the mother’s circulation during pregnancy. This stimulates maternal antibody formation against the Rh factor. These antibodies reach the fetus via the placenta and cause destruction of the fetal red blood cells (hemolysis). This consequently causes anemia in the fetus. To overcome this anemia, the fetal bone marrow releases immature red blood cells (erythroblasts) into the fetal circulation. The hemoglobin from the destroyed red blood cells is broken down to bilirubin, which is cleared from the fetal circulation by crossing the placenta into the mother’s blood. After birth, however, bilirubin builds up in the newborn’s circulation and high levels of bilirubin may sometimes be deposited in the basal ganglia of the brain causing Kernicterus. (For more information, please choose “kernicterus” as your search term in the Rare Disease Database.)
In women who have developed Rh-sensitization, succeeding pregnancies with Rh incompatibility produce progressively more seriously affected infants, unless treatment with an anti-Rh-gammaglobulin (RhoGAM) is given to the mother within 72 hours after each childbirth or termination of pregnancy. The more severely affected fetuses develop profound anemia in the womb and are delivered with gross edema (swelling) of the entire body (hydrops fetalis). This may be suspected before delivery if excessive fluid around the fetus in the amnion sac (polyhydramnios) is present (detected through x- rays). Sometimes a picture of the fetus in the uterus (amniogram) reveals severe scalp edema.
Newborn infants with Rh disease are extremely pale and may have severe generalized edema, including the presence of liquid in the pleural cavity around the lungs (pleural effusion) and an accumulation of serous fluid in the abdominal cavity (ascites). The liver and spleen are enlarged because of production of red blood cells outside the bone marrow. Congestive heart failure may sometimes occur. Because of anemia and prematurity, lack of oxygen in the lungs (asphyxia) is likely during labor and delivery. The prematurity and asphyxia along with an abnormal decrease of the amount of protein in the blood (hypoproteinemia) may predispose the infant to respiratory distress syndrome (RDS), the signs of which may be difficult to distinguish from those of congestive heart failure.
Less severely affected newborn infants may be anemic, but do not have edema or other signs of hydrops. Others may have little or no anemia at birth. Affected infants usually develop severe hyperbilirubinemia shortly after delivery because of the continuing hemolytic effect of Rh-antibodies that have crossed the placenta.
Succeeding pregnancies tend to produce more seriously affected fetuses. Erythroblastosis can be prevented by injecting the mother with a high-titer anti-Rh-gammaglobulin preparation within 72 hours after delivery to prevent her from developing antibodies.
Rh incompatibility occurs when a woman with Rh-negative blood conceives a child with Rh-positive blood. Red blood cells from the fetus cross the placenta and enter into the mother’s circulation stimulating maternal antibody formation against the Rh factor. These antibodies reach the fetus via the placenta and cause destruction of the fetal red blood cells, consequently causing anemia and bilirubin in the fetal blood (jaundice) which makes the infant appear yellow. Rh-negative and -positive blood types are determined by genetic factors.
Since the introduction of Rh immunoglobulin as a treatment for Rh disease in 1968, the number of babies born with the disorder has dropped dramatically from greater than 20,000 babies per year in the United Sates to approximately 4,000 babies per year.
Rh disease occurs only in infants who have Rh-positive blood and whose mothers have Rh-negative blood. Some clinicians estimate that in the U.S. only about 13% of marriages result in pairing of an Rh-positive man and an Rh-negative woman. They estimate that one in about 27 children born to these couples will suffer from Rh disease.
The blood group of the mother can be determined conveniently and with ease. If the mother's blood is found to be Rh-positive, there is no chance of the baby being born with Rh disease. If the mother's blood is found to be Rh-negative, the father's blood group must be determined. If the father's blood group turns out to be Rh-positive, there is a chance that the fetus will be Rh incompatible. In such cases, or if the father is unavailable for testing, a sample of fetal blood is taken in order to determine if Rh incompatibility is present.
All Rh-negative mothers of Rh-positive babies should receive two injections of a biological known as Rh immune globulin (RhIG). The first should be administered at about the 28th week of pregnancy. The second should be given within 72 hours after delivery.
There have been major improvements in the treatment of fetuses with severe Rh disease. Newer treatments involve blood transfusions usually using cordocentesis. This involves using a fine, hollow needle under the guidance of an ultrasound.
An infant with hydrops fetalis or severe erythroblastosis fetalis (without hydrops) due to Rh disease is usually critically ill and should be treated in a perinatal intensive care facility whenever possible. Fetal heart rate should be monitored during labor. If signs of lack of oxygen (asphyxia) occur, or if the infant is severely affected, cesarean section delivery should be performed. The mainstay of treatment is exchange transfusion. This is a blood transfusion using twice the infant's calculated blood volume which removes 85% of the infant's blood, including circulating antibodies, sensitized red blood cells, accumulated bilirubin, and replenishes red blood cells.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
Harkness UF, Sipinnato JA. Prevention and management of RhD isoimmunization. Clin Perinatol. 2004;31:721-42.
Bussel JB. Fetal and neonatal cytopenias: what have we learned? Am J perinatol. 2003;20:425-31.
Harrod KS, Hanson L, VandeVusse L, et al. Rh negative status and isoimmunization update: a case-based approach to care. J Perinat Neonatal Nurs. 2-003;17:166-78.
Gottstein R, Cooke RW. Systmeatic review of intravenous immunoglobulin in haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed. 2003;88:F6-10.
Cotorruelo CM, Biondi CS, Garcia Borras S, et al. Clinical aspects of Rh genotyping. Clin Lab. 2002;48:271-81.
Greenough A. The role of immunoglobulinms in neonatal Rhesus haemolytic disease. BioDrugs. 2001;15:533-41.
FROM THE INTERNET
Salem L. Rh Incompatibility. emedicine. Last Updated: February 7, 2005. 9pp.
Rh Disease. Quick Reference and Fact Sheets. March of Dimes. 2005. 3pp.
The information in NORD’s Rare Disease Database is for educational purposes only and is not intended to replace the advice of a physician or other qualified medical professional.
The content of the website and databases of the National Organization for Rare Disorders (NORD) is copyrighted and may not be reproduced, copied, downloaded or disseminated, in any way, for any commercial or public purpose, without prior written authorization and approval from NORD. Individuals may print one hard copy of an individual disease for personal use, provided that content is unmodified and includes NORD’s copyright.
National Organization for Rare Disorders (NORD)
55 Kenosia Ave., Danbury CT 06810 • (203)744-0100